Gossamer Bio, Inc.

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics for patients with rare and underserved diseases. Headquartered in San Diego, California, the company's mission is to enhance the lives of individuals suffering from pulmonary hypertension.

The company's primary focus is on seralutinib (GB002), an investigational inhaled small molecule designed to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib is an inhaled PDGFRα/β, CSF1R, and c-KIT inhibitor. Gossamer Bio also holds an option agreement to acquire Respira Therapeutics and its lead product candidate, RT234, an investigational inhaled vardenafil dry-powder therapy for pulmonary hypertension.

Recent developments include the company's announcement in August 2026 of a structured private placement of up to $250 million to fund seralutinib through potential FDA approval. In July 2026, Gossamer Bio reacquired worldwide development and commercial rights for seralutinib from Chiesi and is proceeding toward a planned New Drug Application (NDA) submission for seralutinib for PAH in September 2026. Faheem Hasnain serves as the Co-Founder, CEO, President, and Chairman of the company.